CheckMate 8HW: first-line nivolumab plus ipilimumab in MSI-H/dMMR mCRC

CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRCПодробнее

HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRCПодробнее

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed...Подробнее

GI ASCO 2024 Highlights with Dr. Pamela Kunz – CheckMate 8HW, EMERALD-1, NETTER-2Подробнее

KEYNOTE-177 and CheckMate 8HW: promising first-Line immunotherapy for MSI-H mCRCПодробнее

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRCПодробнее